Katri Abel-Ollo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Katri Abel-Ollo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Anneli Uusküla
Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia
4 shared publications - Don C. Des Jarlais
New York University School of Global Public Health, New York University, New York, USA
2 shared publications - Kristi Rüütel
National Institute for Health Development, Tallinn, Estonia
2 shared publications A Riikoja
Estonian Forensic Science Institute, Toxicology Department, Tervise 20, 13419, Tallinn, Estonia
1 shared publicationA Uusküla
Department of Family medicine and Public Health, University of Tartu, Ravila 19, 50411, Tartu, Estonia
1 shared publicationA. Talu
Estonian Drug Monitoring Centre , National Institute for Health Development , Tallinn , Estonia
1 shared publication
Latest Publications
- Open Access
- 22 September 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 157 (Pt A) , 105520
Discordance between self-reported and detected synthetic opioids reveals cychlorphine emergence among people who inject drugs in Estonia
- 22 September 2026
- Published by Elsevier in International Journal of Drug Policy
- Vol. 157 (Pt A) , 105520
Open AccessDiscordance between self-reported and detected synthetic opioids reveals cychlorphine emergence among people who inject drugs in Estonia
- Open Access
- 23 September 2025
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 35 (6) , 1233-1240
The nitazene epidemic in Estonia: a first report
Since 2022, Estonia, a north-east European nation of 1.3 million people, has faced challenges with nitazenes, a class of novel synthetic opioids, which present a new threat to public health. The purpose of this article is to provide the timeline of the nitazene epidemic in Estonia, examining the prevalence and health consequences of nitazene use in the country. This case study uses a multifaceted approach. Data sources include administrative statistics, surveillance and research data, national service provision information, and government documentation from 2015 to 2024, with a focus on health consequences from 2019 to 2024. Quantitative data is complemented by qualitative interviews with nitazene users. The number of drug-related deaths in Estonia has more than doubled since 2022 (39 vs. 80 cases), exceeding over 100 cases in 2023. The increasing prevalence of nitazenes from 2022 is confirmed by syringe residue studies and seizure data. Nitazenes are often sold on the drug market, usually with no or limited information to the user about the substance being sold. Users frequently describe the effect of nitazenes as stronger, faster, sharper and more short-lived compared to fentanyl. Harm reduction services have seen increased utilization since 2022, with first responders facing growing challenges linked to the emergence of the nitazene phenomenon. This study provides the first comprehensive description of the nitazene epidemic. Results indicate a need for more evidence-based information on the use of nitazenes and their consequences to effectively address emerging challenges.
- 23 September 2025
- Published by Oxford University Press (OUP) in European Journal of Public Health
- Vol. 35 (6) , 1233-1240
Open AccessThe nitazene epidemic in Estonia: a first report
Since 2022, Estonia, a north-east European nation of 1.3 million people, has faced challenges with nitazenes, a class of novel synthetic opioids, which present a new threat to public health. The purpose of this article is to provide the timeline of the nitazene epidemic in Estonia, examining the prevalence and health consequences of nitazene use in the country. This case study uses a multifaceted approach. Data sources include administrative statistics, surveillance and research data, national service provision information, and government documentation from 2015 to 2024, with a focus on health consequences from 2019 to 2024. Quantitative data is complemented by qualitative interviews with nitazene users. The number of drug-related deaths in Estonia has more than doubled since 2022 (39 vs. 80 cases), exceeding over 100 cases in 2023. The increasing prevalence of nitazenes from 2022 is confirmed by syringe residue studies and seizure data. Nitazenes are often sold on the drug market, usually with no or limited information to the user about the substance being sold. Users frequently describe the effect of nitazenes as stronger, faster, sharper and more short-lived compared to fentanyl. Harm reduction services have seen increased utilization since 2022, with first responders facing growing challenges linked to the emergence of the nitazene phenomenon. This study provides the first comprehensive description of the nitazene epidemic. Results indicate a need for more evidence-based information on the use of nitazenes and their consequences to effectively address emerging challenges.
- Open Access
- 27 May 2022
- Published by Uniwersytet Gdanski in Journal of Geography, Politics and Society
- Vol. 12 (1) , 8–16
The impact of the COVID-19 pandemic on drug demand and supply in Estonia
The COVID-19 pandemic has changed the world and imposed restrictions and rules that democratic countries could not have foreseen. The global health and social care system was put under enormous pressure, and preventing it from a total collapse became the primary objective. This paper looks at how the pandemic affected the illicit drug market, people who use drugs and services designed to support and help them. Based on the available studies and administrative statistics from 2019 and 2020, illicit drug use and need for services remained the same despite the pandemic. Services quickly adopted new operating rules and became available for the target group. There is ample evidence that in some cases illicit drug use (e.g. cannabis) even gained in popularity as a coping method for anxiety and stress. The drug supply fell only temporarily due to the COVID-19, to which it quickly adapted through new IT and crypto possibilities (dark web).
- 27 May 2022
- Published by Uniwersytet Gdanski in Journal of Geography, Politics and Society
- Vol. 12 (1) , 8–16
Open AccessThe impact of the COVID-19 pandemic on drug demand and supply in Estonia
The COVID-19 pandemic has changed the world and imposed restrictions and rules that democratic countries could not have foreseen. The global health and social care system was put under enormous pressure, and preventing it from a total collapse became the primary objective. This paper looks at how the pandemic affected the illicit drug market, people who use drugs and services designed to support and help them. Based on the available studies and administrative statistics from 2019 and 2020, illicit drug use and need for services remained the same despite the pandemic. Services quickly adopted new operating rules and became available for the target group. There is ample evidence that in some cases illicit drug use (e.g. cannabis) even gained in popularity as a coping method for anxiety and stress. The drug supply fell only temporarily due to the COVID-19, to which it quickly adapted through new IT and crypto possibilities (dark web).
- Open Access
- 30 June 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 517
Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia
Estonia has experienced an HIV epidemic among intravenous drug users (IDUs) with the highest per capita HIV prevalence in Eastern Europe. We assessed the effects of expanded syringe exchange programs (SEP) in the capital city, Tallinn, which has an estimated 10,000 IDUs.
- 30 June 2011
- Published by Springer Nature in BMC Public Health
- Vol. 11 (1) , 517
Open AccessExpanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia
Estonia has experienced an HIV epidemic among intravenous drug users (IDUs) with the highest per capita HIV prevalence in Eastern Europe. We assessed the effects of expanded syringe exchange programs (SEP) in the capital city, Tallinn, which has an estimated 10,000 IDUs.
- 22 November 2010
- Published by BMJ in Sexually Transmitted Infections
- Vol. 86 (Suppl 3) , iii79-iii84
Emergent properties of HIV risk among injection drug users in Tallinn, Estonia: synthesis of individual and neighbourhood-level factors
Objectives HIV/AIDS risk is embodied within multiple levels including structural and social levels. The aim of this study was to assess the effects of neighbourhood characteristics on HIV prevalence among injection drug users (IDU) residing in the area of Tallinn, Estonia in 2007. Methods A cross-sectional, multilevel design collecting individual-level data—a behaviour survey including data on self-reported residency and HIV antibody testing among 350 IDU and neighbourhood-level data—aggregate measures on socio-demo-economic residential characteristics from the 2000 Estonian census. Geocoding and multilevel modelling analysis was employed. Results Among the 350 IDU recruited, earlier age at first injection, fentanyl as the main injection drug, receptive syringe sharing, main income source other than legal employment and ever attended a syringe exchange programme remained significantly associated with increased odds of anti-HIV positivity in the multivariable analysis involving individual effects with no predictors at the neighbourhood level. In the multilevel model, individual (earlier at IDU initiation AOR 1.86, 95% CI 1.01 to 3.44; injecting opioids AOR 4.43, 95% CI 2.74 to 7.18; receptive syringe sharing AOR 2.51, 95% CI 1.86 to 3.37; main income source other than work AOR 2.04, 95% CI 1.32 to 3.14; ever attended a syringe exchange programme AOR 2.58, 95% CI 1.83 to 3.61) and neighbourhood level (higher unemployment rate AOR 5.95, 95% CI 2.47 to 14.31; greater residential change AOR 1.89, 95% CI 1.09 to 3.26) emerged as significant predictors of individual HIV-positive status. Conclusions Our results indicate that both individual-level and emergent neighbourhood-level factors contribute to HIV risk among IDU and are amenable for preventive interventions.
- 22 November 2010
- Published by BMJ in Sexually Transmitted Infections
- Vol. 86 (Suppl 3) , iii79-iii84
Emergent properties of HIV risk among injection drug users in Tallinn, Estonia: synthesis of individual and neighbourhood-level factors
Objectives HIV/AIDS risk is embodied within multiple levels including structural and social levels. The aim of this study was to assess the effects of neighbourhood characteristics on HIV prevalence among injection drug users (IDU) residing in the area of Tallinn, Estonia in 2007. Methods A cross-sectional, multilevel design collecting individual-level data—a behaviour survey including data on self-reported residency and HIV antibody testing among 350 IDU and neighbourhood-level data—aggregate measures on socio-demo-economic residential characteristics from the 2000 Estonian census. Geocoding and multilevel modelling analysis was employed. Results Among the 350 IDU recruited, earlier age at first injection, fentanyl as the main injection drug, receptive syringe sharing, main income source other than legal employment and ever attended a syringe exchange programme remained significantly associated with increased odds of anti-HIV positivity in the multivariable analysis involving individual effects with no predictors at the neighbourhood level. In the multilevel model, individual (earlier at IDU initiation AOR 1.86, 95% CI 1.01 to 3.44; injecting opioids AOR 4.43, 95% CI 2.74 to 7.18; receptive syringe sharing AOR 2.51, 95% CI 1.86 to 3.37; main income source other than work AOR 2.04, 95% CI 1.32 to 3.14; ever attended a syringe exchange programme AOR 2.58, 95% CI 1.83 to 3.61) and neighbourhood level (higher unemployment rate AOR 5.95, 95% CI 2.47 to 14.31; greater residential change AOR 1.89, 95% CI 1.09 to 3.26) emerged as significant predictors of individual HIV-positive status. Conclusions Our results indicate that both individual-level and emergent neighbourhood-level factors contribute to HIV risk among IDU and are amenable for preventive interventions.
- Open Access
- 29 June 2009
- Published by Taylor & Francis in AIDS Care
- Vol. 21 (7) , 851-857
Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia
We used the findings from two, cross-sectional studies of HIV serostatus and risk behaviours to assess the effects of knowledge of HIV serostatus and risk behaviours (relating to sex and injection drug use) among injecting drug users (IDUs). Respondent-driven sampling was used simultaneously at two sites in Estonia (the capital Tallinn, and the second-largest city of Ida-Virumaa County, Kohtla-Järve). The research tool was an interviewer-administered survey. Biological samples were collected for HIV testing. Participants were categorised into three groups based on HIV testing results and self-report on HIV serostatus: HIV-negative (n=133); HIV-positive unaware of their serostatus (n=75); and HIV-positive aware of their serostatus (n=168). In total, 65% of the participants tested positive for HIV. Of those 69% were aware of their positive serostatus. HIV-positive IDUs aware of their serostatus exhibited more risk behaviours than their HIV-positive counterparts unaware of their serostatus or HIV-negative IDUs. Effective prevention of HIV among IDUs should therefore, include programmes to reduce high-risk sexual and drug use behaviours at the public health scale and enhanced prevention efforts focusing on HIV-infected individuals.
- 29 June 2009
- Published by Taylor & Francis in AIDS Care
- Vol. 21 (7) , 851-857
Open AccessKnowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia
We used the findings from two, cross-sectional studies of HIV serostatus and risk behaviours to assess the effects of knowledge of HIV serostatus and risk behaviours (relating to sex and injection drug use) among injecting drug users (IDUs). Respondent-driven sampling was used simultaneously at two sites in Estonia (the capital Tallinn, and the second-largest city of Ida-Virumaa County, Kohtla-Järve). The research tool was an interviewer-administered survey. Biological samples were collected for HIV testing. Participants were categorised into three groups based on HIV testing results and self-report on HIV serostatus: HIV-negative (n=133); HIV-positive unaware of their serostatus (n=75); and HIV-positive aware of their serostatus (n=168). In total, 65% of the participants tested positive for HIV. Of those 69% were aware of their positive serostatus. HIV-positive IDUs aware of their serostatus exhibited more risk behaviours than their HIV-positive counterparts unaware of their serostatus or HIV-negative IDUs. Effective prevention of HIV among IDUs should therefore, include programmes to reduce high-risk sexual and drug use behaviours at the public health scale and enhanced prevention efforts focusing on HIV-infected individuals.